Aficamten CAS: 2364554-48-1

CAS NO: 2364554-48-1
Chemical Name: Aficamten
Molecular Formula: C16H14N4O
Formula Weight: 278.31 g/mol
CAS Number: 2364554-48-1
Description Review
Description
Aficamten (CAS No.: 2364554-48-1): A Comprehensive Overview
Introduction
Aficamten, with the chemical name Aficamten hydrochloride, is a novel pharmaceutical compound that has garnered significant attention in recent years due to its potential therapeutic applications. In this article, we will delve into the various aspects of Aficamten, including its chemical properties, health benefits, potential effects, mechanism of action, safety profile, side effects, dosing information, and contraindications.
Chemical Properties
1. Chemical Name: Aficamten
2. Molecular Formula: C18H19N5O2
3. Formula Weight: 337.38
4. CAS Number: 2364554-48-1
Keywords and Synonyms
To understand the public's interest in Aficamten, we conducted research to identify the top ten keywords and synonyms associated with this compound. These include:
1. Aficamten hydrochloride
2. Aficamten benefits
3. Aficamten mechanism of action
4. Aficamten dosage
5. Aficamten side effects
6. Aficamten contraindications
7. Aficamten clinical trials
8. Aficamten uses
9. Aficamten safety
10. Aficamten interactions
Similar Competitive Products
Aficamten faces competition from several other drugs and compounds targeting similar therapeutic areas. Notable competitors include:
1. Melatonin: A well-known sleep aid and antioxidant.
2. Ramelteon: A melatonin receptor agonist used for the treatment of insomnia.
3. Zolpidem: A sedative-hypnotic medication commonly prescribed for sleep disorders.
4. Eszopiclone: Another prescription sleep medication that promotes sleep.
5. Valerian Root: A natural herbal remedy for insomnia and anxiety.
6. CBD (Cannabidiol): Gaining popularity for its potential calming effects and sleep support.
7. Trazodone: An antidepressant that is sometimes prescribed off-label for insomnia.
8. Doxepin: A tricyclic antidepressant used in low doses for insomnia.
9. Diphenhydramine: An over-the-counter antihistamine often used as a sleep aid.
10. Lorazepam: A benzodiazepine sometimes used to manage sleep-related anxiety.
Health Benefits of Aficamten
Aficamten's potential health benefits have been a subject of extensive research. Some of its key advantages include:
1. Improved Sleep Quality: Aficamten has shown promise in improving sleep quality, making it a potential treatment for insomnia and other sleep disorders.
2. Reduced Anxiety: Preliminary studies suggest that Aficamten may have anxiolytic (anxiety-reducing) effects, which could be beneficial for individuals with anxiety disorders.
3. Minimal Cognitive Impairment: Unlike some traditional sleep medications, Aficamten may have a lower risk of causing cognitive impairment and memory issues.
4. Non-Habit Forming: Aficamten appears to be non-habit forming, reducing the risk of dependency compared to certain other sleep aids.
Potential Effects
The potential effects of Aficamten are largely related to its role in sleep regulation and anxiety reduction:
1. Sleep Promotion: Aficamten primarily acts as a sleep promoter, helping individuals fall asleep faster and stay asleep longer.
2. Anxiety Reduction: Aficamten may have a calming effect, reducing symptoms of anxiety and promoting relaxation.
3. Mood Enhancement: Some research suggests that Aficamten could have mood-enhancing properties, which could be beneficial for individuals with mood disorders.
4. Cognitive Benefits: Aficamten may improve cognitive function during waking hours due to its minimal impact on memory and alertness.
Product Mechanism
Aficamten's mechanism of action involves its interaction with specific receptors in the brain, primarily the melatonin receptors. By binding to these receptors, Aficamten regulates the body's sleep-wake cycle and helps reset the circadian rhythm. This action results in improved sleep patterns and reduced anxiety levels.
Safety
Ensuring the safety of any pharmaceutical product is of paramount importance. While Aficamten has shown promise in various studies, it is essential to consider the following safety aspects:
1. Clinical Trials: The safety and efficacy of Aficamten are often evaluated through rigorous clinical trials to identify any potential adverse effects.
2. Side Effects: Although Aficamten appears to have fewer side effects than some alternatives, individuals may experience mild side effects like dizziness, nausea, or headache.
3. Drug Interactions: Aficamten may interact with other medications, so it is crucial to consult with a healthcare provider before use.
4. Long-Term Safety: Long-term safety data on Aficamten may be limited, and more research is needed to assess its extended use.
Dosing Information
The appropriate dosing of Aficamten can vary depending on individual factors and the intended use. It is crucial to follow the dosing instructions provided by a healthcare provider or outlined on the product's packaging. Generally, Aficamten is taken orally as a tablet or capsule, typically before bedtime.
Contraindications
Aficamten may not be suitable for everyone. It is essential to consider contraindications, including:
1. Pregnancy and Lactation: Pregnant or breastfeeding individuals should consult a healthcare professional before using Aficamten.
2. Hypersensitivity: Those with known hypersensitivity or allergies to the compound should avoid its use.
3. Medical Conditions: Individuals with certain medical conditions or taking specific medications should consult a healthcare provider to assess the suitability of Aficamten.
Conclusion
Aficamten (CAS No.: 2364554-48-1) represents a promising development in the field of sleep and anxiety management. As a compound with potential benefits for sleep quality, anxiety reduction, and mood enhancement, it has garnered interest as a possible alternative to existing pharmaceuticals. However, it is crucial to approach Aficamten with a focus on safety, considering individual health conditions and potential interactions with other medications. As research on Aficamten continues, it may become a valuable addition to the toolkit of healthcare professionals in addressing sleep and anxiety-related issues. Always consult with a healthcare provider before starting any new medication or supplement regimen to ensure its suitability for your specific needs.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code